Aequus Pharmaceuticals Inc

NEW
TSXV:AQS (Canada)  
C$ 0.0050 (0%) Jul 24
At Loss
Market Cap:
C$ 663.00K ($ 470.00K)
Enterprise V:
C$ 7.21M ($ 5.11M)
Volume:
0
Avg Vol (2M):
0
Trade In:

Business Description

Aequus Pharmaceuticals Inc
NAICS : 325410 SIC : 3741
ISIN : CA0076361033

Total Employee Number:

14
Description
Aequus Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The firm's operating segments are the Commercial platform and Development pipeline. It generates a majority of its revenue from the Commercial platform segment. The company earns revenues from the sale of dry eye products and by providing promotional services to sell third-party-owned products namely Tacrolimus IR and Vistitan.

Financial Strength

Name Current Vs Industry Vs History
Equity-to-Asset
-35.17
Debt-to-Equity
-0.88
Debt-to-EBITDA
-27.41
Piotroski F-Score
6/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score
-296.11
Distress
Grey
Safe
WACC vs ROIC
WACC
ROIC

Momentum Rank

Name Current Vs Industry Vs History

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio
0.03
Quick Ratio
0.03
Days Inventory
72.82
Days Sales Outstanding
32.97
Days Payable
672.45

Dividend & Buy Back

Name Current Vs Industry Vs History
Shareholder Yield %
-90.12

Profitability Rank

Name Current Vs Industry Vs History
Gross Margin %
56.8
Operating Margin %
-62.57
Net Margin %
-71.49
EBITDA Margin %
-23.94
FCF Margin %
-12.51
OCF Margin %
-12.51
ROA %
-137.22
ROIC %
-9.08
3-Year ROIIC %
-19.8
ROC (Joel Greenblatt) %
-70.05
Moat Score
2
Tariff Resilience Score
5

GF Value Rank

Name Current Vs Industry Vs History
PS Ratio
0.63
EV-to-EBIT
-18.67
EV-to-EBITDA
-32.75
EV-to-Revenue
7.84
EV-to-FCF
-62.66
Price-to-GF-Value
0.25
Earnings Yield (Greenblatt) %
-5.36
FCF Yield %
-17.35

Financials

TSXV:AQS's 30-Y Financials
Income Statement Breakdown FY
Not Enough Data
Balance Sheet Breakdown
Not Enough Data
Cashflow Statement Breakdown
Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
Not Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2026
2025
2024
2023
2022
2021
2020
2019
2018
2017

Aequus Pharmaceuticals Inc Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil C$) 0.919
EPS (TTM) (C$) -0.01
Beta -1.752
3-Year Sharpe Ratio -0.49
3-Year Sortino Ratio -0.69
Volatility % -
14-Day RSI -
14-Day ATR (C$) -
20-Day SMA (C$) 0.005
12-1 Month Momentum % -
52-Week Range (C$) 0.005 - 0.005
Shares Outstanding (Mil) 132.63

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 6
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Aequus Pharmaceuticals Inc Filings

Filing Date Document Date Form
No Filing Data

Aequus Pharmaceuticals Inc Stock Events

Financials Calendars
Event Date Price (C$)
No Event Data

Aequus Pharmaceuticals Inc Frequently Asked Questions

What is Aequus Pharmaceuticals Inc(TSXV:AQS)'s stock price today?
The current price of TSXV:AQS is C$0.01. The 52 week high of TSXV:AQS is C$0.01 and 52 week low is C$0.01.
When is next earnings date of Aequus Pharmaceuticals Inc(TSXV:AQS)?
The next earnings date of Aequus Pharmaceuticals Inc(TSXV:AQS) is .
Does Aequus Pharmaceuticals Inc(TSXV:AQS) pay dividends? If so, how much?
Aequus Pharmaceuticals Inc(TSXV:AQS) does not pay dividend.

Press Release

Subject Date
Aequus and reVision to Collaborate on Stargardt Disease Program 2021-08-17
10/Page

Articles on Aequus Pharmaceuticals Inc

No articles.